“Long-term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: an Integrated Analysis with Over 9600 Patient-Years of exposure”, J of Skin, vol. 10, no. 2, p. s727, Mar. 2026, doi: 10.25251/evafb145.